Crossmark

Management of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC)

Crossref DOI link: https://doi.org/10.1007/s40121-024-01105-y

Published Online: 2025-01-16

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vinterberg, Johanna Eliasson

Oddsdottir, Julia

Nye, Maria

Pinton, Philippe https://orcid.org/0000-0002-4227-7687
License Information

Text and Data Mining valid from 2025-01-16

Version of Record valid from 2025-01-16
More Information

Article History

Received: 12 November 2024

Accepted: 18 December 2024

First Online: 16 January 2025

Declarations

:

: Johanna Eliasson Vinterberg is an employee of Ferring Pharmaceuticals; Julia Oddsdottir and Maria Nye are employees of IQVIA. IQVIA received funding from Ferring Pharmaceuticals for running the study; Philippe Pinton is an employee of Ferring Pharmaceuticals, belongs to the board of directors of PharmaBiome, and owns stocks in Takeda Pharmaceutical Company Ltd.

: This study was a review of previously published literature and did not involve human subjects. Therefore, ethical approval was not required.

Document is current

Any future updates will be listed below